CIBC Private Wealth Group
WHWK

CIBC Private Wealth Group’s Whitehawk Therapeutics WHWK Stock Holding History

CIBC Private Wealth Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-667
Closed -$31K – 970
2018
Q3 		$31K Buy
+667
New +$37.4K ﹤0.01% 955

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

CIBC Private Wealth Group's WHWK Position: Q4 2018 in Review

CIBC Private Wealth Group sold out of Whitehawk Therapeutics (WHWK) in Q4 2018, closing a stake of 667 shares — an estimated $31K sold.

CIBC Private Wealth Group first reported a position in WHWK in Q3 2018 and held it in 1 quarter. The position peaked at $31K in Q3 2018. 24 funds tracked by Wall St. Rank hold WHWK as of Q4 2018.

  • CIBC Private Wealth Group reported no remaining Whitehawk Therapeutics position as of Q4 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 667 Whitehawk Therapeutics shares in Q4 2018, an estimated $31K.
  • CIBC Private Wealth Group first reported a position in Whitehawk Therapeutics in Q3 2018 and held it in 1 quarter.
  • CIBC Private Wealth Group's Whitehawk Therapeutics position peaked at $31K in Q3 2018.
  • 24 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2018.

Based on CIBC Private Wealth Group's 13F filing for Q4 2018, filed 5 Feb 2019.